Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,506 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Saline alone Clear all
Completed Not applicable Interventional

Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion in Human Muscle

NCT01412008
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Botox (botulinum toxin)
Drug
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 8, 2026, 8:05 PM EDT
Not listed Phase 2 Interventional

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

NCT04646603
View directory record Official record
Conditions
COVID-19, ARDS, Human, Stem Cells, Regeneration
Interventions
MRG-001, Placebo
Drug
Lead sponsor
MedRegen LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Gentamicin Intravesical Efficacy for Infection of Urinary Tract

NCT04246996
View directory record Official record
Conditions
Postoperative Urinary Tract Infection, Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions
gentamicin sulfate, Catheter clamping only
Drug · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

NCT02357459
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006, Placebo, TCA IR 40
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 8, 2026, 8:05 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT05705024
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Mesenchymal Stromal Cells, Control Solution
Biological · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 8, 2026, 8:05 PM EDT
Suspended Phase 2 Interventional

Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder

NCT03787290
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tocilizumab, Placebo, Whole-Body Hyperthermia
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants

NCT02561923
View directory record Official record
Conditions
Healthy
Interventions
Rivaroxaban, Tranexamic acid, Kcentra, a 4-factor PCC, Saline
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 8, 2026, 8:05 PM EDT
Withdrawn Phase 4 Interventional

Pericapsular Nerve Group Block (PENG) for Hip Surgery

NCT05118620
View directory record Official record
Conditions
Hip Arthropathy, Postoperative Pain, Acute, Pain, Postoperative
Interventions
Active bupivacaine 0.375% PENG block, Placebo normal saline PENG block
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 8, 2026, 8:05 PM EDT
Recruiting Phase 1 Interventional

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

NCT05366179
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CAR.B7-H3T cells infusion
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

NCT07197762
View directory record Official record
Conditions
Neisseria Meningitidis
Interventions
Trumenba, PENBRAYA
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 25 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 4 Interventional

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

NCT01968902
View directory record Official record
Conditions
Muscle Spasticity, Multiple Sclerosis
Interventions
incabotulinumtoxinA, Placebo
Biological
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 8, 2026, 8:05 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

NCT00599131
View directory record Official record
Conditions
Cancer of Larynx
Interventions
Cisplatin, Cetuximab, 5-Fluorouracil, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 8, 2026, 8:05 PM EDT
Terminated Phase 1 Interventional

Study Evaluating Vaccine in Adults With HIV

NCT00195312
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Not applicable Interventional Results available

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NCT01949844
View directory record Official record
Conditions
Coronary Artery Disease, CAD
Interventions
regadenoson, Optimark®, Myocardial perfusion MRI
Drug · Device
Lead sponsor
Daniel S. Berman
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 1 Interventional

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

NCT06604832
View directory record Official record
Conditions
Skin Aging, Skin Wrinkling
Interventions
PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo)
Drug
Lead sponsor
Kalpna Kay Durairaj, MD, FACS
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Not applicable Interventional

Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load

NCT03461783
View directory record Official record
Conditions
Wound Infection
Interventions
Zorflex Activated Carbon Dressing, Standard of Care
Device
Lead sponsor
Brock Liden, DPM
Individual
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Circleville, Ohio • Logan, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

NCT02863809
View directory record Official record
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 8, 2026, 8:05 PM EDT
Completed No phase listed Observational

Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI

NCT03023566
View directory record Official record
Conditions
Brain Diseases
Interventions
Dotarem
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 8, 2026, 8:05 PM EDT
Enrolling by invitation Not applicable Interventional

Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Pain Following Thoracic Trauma

NCT06069154
View directory record Official record
Conditions
Rib Fracture, Rib Fracture Multiple
Interventions
Cryoneurolysis, Local anesthetic peripheral nerve block, Sham Cryoneurolysis, Sham peripheral nerve block
Device · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
La Jolla, California • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Not yet recruiting Not applicable Interventional

Clearance in Primary Ciliary Dyskinesia

NCT07699302
View directory record Official record
Conditions
Primary Ciliary Dyskinesia, PCD
Interventions
Exercise, HS pretreatment with Exercise
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

NCT02788188
View directory record Official record
Conditions
Middle East Respiratory Syndrome Coronavirus
Interventions
SAB-301, Normal (9%) Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 8, 2026, 8:05 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:

NCT02432157
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm, Hyponatremia
Interventions
HTS 3%, Standard fluid management
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 8, 2026, 8:05 PM EDT
Withdrawn Early Phase 1 Interventional

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

NCT05013437
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Evomela, Next Generation Sequencing, Prochlorperazine, Acetaminophen, Diphenhydramine
Drug · Device
Lead sponsor
Koen van Besien
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 8, 2026, 8:05 PM EDT